Valeant
FDA rejects Valeant plaque psoriasis lotion over pharmacokinetic concerns
June 19, 2018Manufacturing and Production, Sales and Marketing FDA, Valeant, pharma, psoriasis
Beleaguered pharma firm Valeant has come up against another bump in the road as its plaque psoriasis lotion Duobrii (halobetasol …
Top Ten most popular articles on Pharmafile.com this week
May 11, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AstraZeneca, EMA, GSK, J&J, JJ, Novartis, Shire, Takeda, Valeant, biotech, drugs, pharma, pharmaceutical
It’s been a week in which one of the largest pharmaceutical takeovers in history took place and yet it’s not …
Valeant seeks clean slate with rebrand, new company name
May 9, 2018Medical Communications, Research and Development Valeant, pharma
In the latest attempt to reverse its ailing fortunes and distance itself from its polluted brand, Canadian pharma firm Valeant …
Impax agrees to $35 million settlement over anticompetitive practices with Valeant generic
March 12, 2018Sales and Marketing Impax, Medicis, Solodyn, Valeant, generic, pharma
Impax Pharmaceuticals has acquiesced to paying a $35 million settlement in order to resolve part of an antitrust lawsuit it …
Top Ten most popular articles on Pharmafile.com this week
January 5, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Allergan, J&J, JJ, NICE, Pfizer, Spark Therapeutics, Valeant, top ten
Happy New Year from Pharmafile.com! We hope the first week of 2018 hasn’t been too rough. To the surprise of …
Valeant and Pershing take $290m hit over insider trading
January 2, 2018Manufacturing and Production, Sales and Marketing Bill Ackman, Pershing Square, Valeant, biotech, drugs, pharma, pharmaceutical
Valeant Pharmaceuticals will be hoping it can begin 2018 as a fresh start, after a turbulent few years, to say …
Valeant backs away from female libido pill
November 7, 2017Manufacturing and Production, Sales and Marketing Addyi, Valeant, biotech, drugs, pharma, pharmaceutical
Only two years ago, Valeant was so keen to get involved with a pill reported to increase the female libido …
Valeant begins long comeback trail with FDA approval
November 6, 2017Sales and Marketing Valeant, Vyzulta, biotech, drugs, pharma, pharmaceutical
Valeant has had precious little to be happy about over the last few years, it’s bounced from one piece of …
Valeant focused on bringing new products to market, receives CRL
August 9, 2017Research and Development, Sales and Marketing Valeant, biotech, drugs, pharma, pharmaceutical
In its second quarter financial reports, Valeant strove to strike a positive note. It revealed that it had paid down …
Valeant takes huge loss on previous deal to pay down debts
July 18, 2017Manufacturing and Production, Sales and Marketing Obagi Medical Products, Valeant, biotech, drugs, pharma, pharmaceutical
It is an odd time for Valeant, where selling a part of its business for half of what it paid, …
New data shows pharma has not cut back on controversial payments to physicians
July 6, 2017Medical Communications, Sales and Marketing Allergan, Biogen, Celgene, Sanofi, Valeant
Despite increasing controversy arising over the years due to the questionable relationship between physicians and pharma and the money which …
Psoriasis drug Siliq will be cheapest in class, Valeant reveals
April 24, 2017Sales and Marketing Siliq, Valeant, psoriasis
Canadian pharmaceutical firm Valeant has announced the list price for its psoriasis treat Siliq (brodalumab) will stand at $3,500 a …
Former Valeant CEO Michael Pearson sues over $30m unpaid shares
March 28, 2017Manufacturing and Production, Sales and Marketing Michael Pearson, Valeant
Ex-Valeant CEO Michael Pearson is suing his former company over its failure to deliver three million shares he claims he …
FDA approves Valeant plaque psoriasis drug despite suicide concerns
February 16, 2017Sales and Marketing FDA, Siliq, Valeant, psoriasis
The US Food and Drug Administration (FDA) has announced that it has approved Valeant Pharmaceutical’s injectable psoriasis treatment Siliq (brodalumab) …
Valeant to sell cancer business to Sanpower for $820m
January 10, 2017Manufacturing and Production, Sales and Marketing Dendreon, Sanpower, Valeant
Valeant Pharmaceuticals has announced it is to sell its cancer business Dendreon to Chinese firm Sanpower in a deal worth …
Latest content
FibroFind appoints Lee Borthwick as CEO
